Bridgewater Associates LP Sells 3,270 Shares of Insulet Co. (NASDAQ:PODD)

Bridgewater Associates LP decreased its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 22.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,142 shares of the medical instruments supplier's stock after selling 3,270 shares during the period. Bridgewater Associates LP's holdings in Insulet were worth $2,593,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. QRG Capital Management Inc. bought a new position in Insulet during the 3rd quarter worth about $297,000. Diversified Trust Co boosted its position in Insulet by 90.9% during the 2nd quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier's stock worth $1,842,000 after acquiring an additional 4,348 shares during the last quarter. Linden Thomas Advisory Services LLC grew its stake in shares of Insulet by 65.8% during the 2nd quarter. Linden Thomas Advisory Services LLC now owns 8,812 shares of the medical instruments supplier's stock worth $1,778,000 after acquiring an additional 3,497 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Insulet by 38.8% in the second quarter. Assenagon Asset Management S.A. now owns 179,393 shares of the medical instruments supplier's stock valued at $36,202,000 after purchasing an additional 50,101 shares during the last quarter. Finally, Fisher Asset Management LLC raised its holdings in shares of Insulet by 0.9% in the third quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier's stock valued at $81,719,000 after purchasing an additional 3,113 shares during the last quarter.

Insulet Stock Performance

PODD traded down $0.14 during trading on Friday, hitting $266.78. The stock had a trading volume of 250,910 shares, compared to its average volume of 625,543. The company has a 50 day moving average price of $244.40 and a 200-day moving average price of $213.85. The firm has a market cap of $18.71 billion, a price-to-earnings ratio of 45.68, a P/E/G ratio of 4.08 and a beta of 1.22. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a one year low of $160.19 and a one year high of $279.40.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. UBS Group lifted their price target on shares of Insulet from $211.00 to $223.00 and gave the company a "neutral" rating in a research note on Friday, August 9th. Piper Sandler upped their target price on Insulet from $230.00 to $285.00 and gave the stock an "overweight" rating in a report on Tuesday, September 17th. Citigroup increased their price target on Insulet from $250.00 to $275.00 and gave the company a "buy" rating in a research report on Tuesday, October 1st. Barclays raised their target price on shares of Insulet from $220.00 to $234.00 and gave the company an "equal weight" rating in a research note on Monday, November 11th. Finally, Raymond James upped their price target on shares of Insulet from $213.00 to $260.00 and gave the stock an "outperform" rating in a research report on Monday, October 14th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat.com, Insulet presently has an average rating of "Moderate Buy" and a consensus target price of $253.27.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.